Multiple Sclerosis Comprehensive Care Center
Click on the sign to list the poster and platform presentations by year. Then click on the link to view that presentation.
2024
2023
- Recommendations on NMOSD treatment in Latin America: Consensus-based RAND/UCLA methodology.
- Development of a questionnarie to measure quality of life in neuromyelitis optica spectrum disorder patients. A validation study from Latin America.
- Increased intracranial pressure - A rare complication of optic neuritis in myelin-oligodendrocyte glycoprotein antibody-associated disease (MOGAD).
- Predictors for a relapsing course of myelin-oligodendrocyte glycoprotein antibody-associated disease (MOGAD).
[Platform Presentation]
- Respiratory impairment in multiple sclerosis: A single-center study in 371 people with MS.
- Anti-myelin oligodendrocyte glycoprotein (anti-MOG) meningoencephalitis.
- Treatment response to different immunotherapies in relapsing myelin-oligodendrocyte glycoprotein antibody-associated disease (MOGAD).
- Frequency of oligoclonal bands and IgG index status in the cerebrospinal fluid of Hispanic patients with multiple sclerosis.
- Flurry of neurologic symptoms - KLHL11 paraneoplastic rhombencephalitis.
9th Joint Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) and European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)
Milan, Italy (Oct. 11-13, 2023)
American Academy of Neurology (AAN)
75th Annual Meeting in Boston, Mass. (April 22-28, 2023)
Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS)
Annual Forum in San Diego, Calif. (Feb. 23-25, 2023)
2022
- Comparative adherence trajectories across oral disease-modifying agents in multiple sclerosis.
- Factors associated with prescribing of teriflunomide and dimethyl fumarate versus fingolimod in multiple sclerosis.
- Erdheim-Chester disease with isolated CNS involvement: A case report and systematic review of literature.
- Determinants of disparate disability accumulation in Black, Hispanic, and White patients with multiple sclerosis.
- NeuroLytes: Developing clinical reasoning for medical students on the neurology clerkship.
- Steroid-responsive ecchordosis physaliphora diagnosed as CLIPPERS: A systematic review of literature and case report.
Professional Society for Health Economics and Outcomes Research (ISPOR)
2022 Annual Meeting in Washington, DC (May 16-18, 2022)
American Academy of Neurology (AAN)
74th Annual Meeting in Seattle, Wash. (April 2-7, 2022)
<2021
- Multiple sclerosis in a multi-ethnic population in Houston, Texas: A retrospective analysis, 2019-2020.
- Effect of different variance estimation methods with inverse probability treatment weights (IPTW) on comparative effectiveness measure in multiple sclerosis.
- Factors associated with prescribing of disease-modifying agents among older adults with multiple sclerosis: A real-world analysis of electronic medical records.
- Acute bilateral optic neuritis due to Borrelia Burgdorferi in a patient with multiple sclerosis on ocrelizumab.
- NeuroLytes as a novel, virtual, case-based didactics targeted at medical students undergoing Neurology clerkship.
- Sociodemographic and clinical characteristics of patients with multiple sclerosis by race and ethnicity (NARCRMS Registry).
- Resident lumbar puncture clinic at Geisinger Health System: A single program needs assessment for quality improvement.
- The reality of MS epidemiology in LATAM.
[Oral Presentation]
- Comparative treatment effectiveness of oral fingolimod and injectable disease modifying agents in multiple sclerosis.
- Socio-demographic and clinical characteristics of patients with multiple sclerosis by race and ethnicity (NARCRMS registry).
- Comparative adherence trajectories of oral fingolimod and injectable disease modifying agents in multiple sclerosis.
- Factors associated with prescribing of oral fingolimod in multiple sclerosis.
- Postpartum relapse after first on-study pregnancy in RRMS patients treated with alemtuzumab in the phase 2 and 3 clinical development program over 8 years.
- Incorporation of electrodiagnostic case reviews to the morning report in a neurology residency program.
- Factors associated with prescribing of oral disease modifying agents in multiple sclerosis.
- Healthcare expenditure burden in multiple sclerosis: Marginal costs based on national level data.
- Leprosy in two patients with relapsing remitting multiple sclerosis (RRMS) treated with fingolimod.
- Fingolimod related cryptococcal meningitis and immune reconstitution inflammatory syndrome in two patients with multiple sclerosis.
- Patient-reported overactive bladder in neuromyelitis optica spectrum disorder.
- Prevalence of self-reported sexual dysfunction in neuromyelitis optica spectrum disorder.
- Prevalence of dysphagia in multiple sclerosis and correlation with disability.
[Platform Presentation]
- Five-year outcomes of HALT-MS: High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe relapsing-remitting multiple sclerosis.
[Platform Presentation]
- Neuromyelitis optica presenting as multiple sclerosis worsening on natalizumab.
- Treatment of idiopathic relapsing transverse myelitis.
- Case series of cardiac complications during fingolimod first dose observation period.
- Efficacy of fingolimod in ethnic minorities.
- Two-year follow-up results of the HALT MS clinical trial (ITN033AI).
- Treatment of idiopathic relapsing transverse myelitis.
- Safety and efficacy of 5 mg and 10 mg dalfampridine extended release tablets in patients with multiple sclerosis: First results from a double-blind, placebo-controlled trial.
- The protection of dopamine neurons in dissociated midbrain cultures with neurotrophic factor combinations from MPP+ toxicity.
[Previously Presented]
- Protection of cultured dopamine neurons from MPP+ requires presence of several neurotrophic factors.
- The protection of dopamine neurons in dissociated midbrain cultures with neurotrophic factor combinations from MPP+ toxicity.
- Distal limb discoloration in patients with multiple sclerosis - Case series of 41 patients.
- Incidence of multiple sclerosis in patients presenting with neurogenic bladder.
- The role of postpartum intravenous corticosteroids in the prevention of relapses in multiple sclerosis.
- Recurrent and multiphasic disseminated encephalomyelitis, case series.
- Distal lower limb discoloration in patients with multiple sclerosis.
- Sleep disorders in multiple sclerosis.
- Use of natalizumab in Hispanic patients with relapsing remitting multiple sclerosis.
- Computer-assisted cognitive rehabilitation for multiple sclerosis — Updated findings.
- Effects of natalizumab on relapses and MRI outcomes in Hispanic patients with relapsing multiple sclerosis.
- Final results from the Registry to Evaluate Novantrone Effects in Worsening Multiple Sclerosis study.
- Clinical and radiographic improvement of an acutely aggressive case of multiple sclerosis treated with cyclophosphamide.
- Prevalence of sleep disorders in multiple sclerosis.
- Spasmodic dysphonia in MS: A rare symptom or a possible association?
- Seizures in MS patients: A retrospective study.
- HALT-MS--Intense immunosuppression and stem cell transplantation for RRMS.
- Long-term sc IFN beta-1a treatment in RRMS: Cumulative dose effects.
- Continuous vs non-continuous long-term sc IFN beta-1a treatment in RRMS.
- Diffuse white matter abnormalities and neurologic manifestations in a patient with anti-ro positive antibodies. Case Report.
- Occurrence of herpes zoster in multiple sclerosis patients treated with natalizumab.
- A post-hoc analysis of cumulative dose effects of subcutaneous interferon beta-1a on clinical and MRI outcomes in relapsing-remitting multiple sclerosis: Results over the long term.
- Long-term effects of interferon beta-1a dose on relapse rate in relapsing-remitting multiple sclerosis: Results from a post- hoc analysis of PRISMS study data.
- HALT MS — Phase II clinical trial of high dose immunosuppressive therapy and autologous hematopoietic stem cell transplantation for active relapsing- remitting multiple sclerosis.
- Menstrual cycle and menopause in patients with multiple sclerosis. How do these affect the symptoms of disease?
- Longitudinal individualized analysis of computer-based cognitive rehabilitation in multiple sclerosis.
- RENEW study update XVIII: Ongoing evaluation of the safety and tolerability of mitoxantrone in worsening multiple sclerosis.
- Magnetic resonance imaging findings in patients with clinically isolated syndrome suggestive of multiple sclerosis.
- Site performance in an investigator-run multiple sclerosis clinical trial.
- Phase II clinical trial (HALT-MS: Immune tolerance network) of high dose immunosuppressive therapy (HDIT) and autologous hematopoetic stem cell transplantation (AHSCT) for active relapsing-remitting (RR) multiple sclerosis (MS): Early results.
- Frequency and severity of restless legs syndrome in multiple sclerosis: A population study from southeast Texas.
- Multiple sclerosis and antiphospholipid syndrome: Case report.
- Encefalomielitis diseminada recurrente y multifásica reporte de 2 casos.
[Recurrent Disseminated Encephalomyelitis: Report of 2 Cases]
- Experience with natalizumab in a group of ms patients from southeast Texas.
- Recurrent disseminated encephalomyelitis: Report of 2 cases.
- Is restless legs syndrome more frequent and severe in the multiple sclerosis population? Study in multiple sclerosis patients from southeast Texas.
- Multiple sclerosis and other autoimmune diseases.
- Behavior of multiple sclerosis during pregnancy and after delivery.
- A phase II study of high-dose immunosuppressive therapy (HDIT) using carmustine, etoposide, cytarabine, and melphalan (beam) + thymoglobulin, and autologous CD34+ hematopoietic stem cell transplant (HCT) for the treatment of poor prognosis multiple sclerosis. HALT-MS.
- Frequency and severity of restless legs syndrome in ms patients from southeast Texas.
- Multiple sclerosis in African Americans: A cohort from southeast Texas.
- Computer-assisted cognitive rehabilitation in patients with multiple sclerosis.
- Results of the Avonex Combination Trial (ACT).
- Ongoing evaluation of the safety and tolerability of mitoxantrone in worsening multiple sclerosis: The RENEW study.
- Rationale, design, and baseline data for the Avonex Combination Trial (ACT).
Baylor College of Medicine (BCM)
4th Annual Center of Excellence in Health Equity, Training and Research Summer Research Summit in Houston, Texas (May 20, 2021)
Professional Society for Health Economics and Outcomes Research (ISPOR)
Virtual 2021 Annual Meeting (May 17-20, 2021)
American Academy of Neurology (AAN)
Virtual 2021 Annual Meeting (April 17-22, 2021)
Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS)
Virtual 2021 Annual Meeting (Feb. 25-27, 2021)
International Society for Pharmacoepidemilogy (ISPE)
International Conference on Pharmacoepidemilogy (ICPE) All Access 2020 virtual event (Sept. 16-17, 2020)
8th Joint Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) and European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)
MS Virtual 2020 (Sept. 11-13, 2020)
Professional Society for Health Economics and Outcomes Research (ISPOR)
Virtual 2020 Annual Meeting (May 18-20, 2020)
American Academy of Neurology (AAN)
72nd Annual Meeting in Toronto, Ontario, Canada (April 25 - May 1, 2020)
American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM)
66th Annual Meeting in Austin, Texas (Oct. 16-19, 2019)
Professional Society for Health Economics and Outcomes Research (ISPOR)
2019 Annual Meeting in New Orleans, La. (May 18-22, 2019)
American Academy of Neurology (AAN)
71st Annual Meeting in Philadelphia, Penn. (May 4-10, 2019)
American Academy of Neurology (AAN)
70th Annual Meeting in Los Angeles, Calif. (April 21-27, 2018)
Consortium of Multiple Sclerosis Centers (CMSC)
31st Annual Meeting in New Orleans, La. (May 24-27, 2017)
Consortium of Multiple Sclerosis Centers (CMSC)
30th Annual Meeting in National Harbor, Md. (June 1-4, 2016)
Consortium of Multiple Sclerosis Centers (CMSC)
27th Annual Meeting in Orlando, Fla. (May 29 - June 1, 2013)
American Academy of Neurology (AAN)
65th Annual Meeting in San Diego, Calif. (March 16-23, 2013)
Baylor College of Medicine (BCM)
Current Neurology 2012 in Houston, Texas (Nov. 3-4, 2012)
University of Pittsburgh
Undergraduate Honors Research Fair in Pittsburgh, Penn. (April 2012)
Society for Neuroscience (SFN)
41st Annual Meeting in Washington, DC (Nov. 12-16, 2011)
University of Pittsburgh
Science 2011: Next Gen Conference in Pittsburgh, Penn. (Oct. 6-7, 2011)
American Academy of Neurology (AAN)
63rd Annual Meeting in Honolulu, Hawaii (April 9-16, 2011)
European Neurological Society (ENS)
20th Annual Meeting in Berlin, Germany (June 19-23, 2010)
Consortium of Multiple Sclerosis Centers (CMSC)
24th Annual Meeting in San Antonio, Texas (June 2-5, 2010)
American Academy of Neurology (AAN)
62nd Annual Meeting in Toronto, Canada (April 10-17, 2010)
Society for Neuroscience (SFN)
39th Annual Meeting in Chicago, Ill. (Oct. 17-21, 2009)
American Neurological Association (ANA)
134th Annual Meeting in Baltimore, Md. (Oct. 11-14, 2009)
European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)
25th Congress in Dusseldorf, Germany (Sept. 9-12, 2009)
Consortium of Multiple Sclerosis Centers (CMSC)
23rd Annual Meeting in Atlanta, Ga. (May 27-30, 2009)
American Academy of Neurology (AAN)
61st Annual Meeting in Seattle, Wash. (April 25 - May 2, 2009)
National Multiple Sclerosis Society (NMSS)
Tykeson Fellows Conference in Chicago, Ill. (Nov. 4-7, 2008)
World Congress on Treatment and Research in Multiple Sclerosis (ACTRIMS + ECTRIMS + LACTRIMS)
Montreal, Quebec, Canada (Sept. 17-20, 2008)
Consortium of Multiple Sclerosis Centers (CMSC)
22nd Annual Meeting in Denver, Colo. (May 28-31, 2008)
American Academy of Neurology (AAN)
60th Annual Meeting in Chicago, Ill. (April 12-19, 2008)
Mexican Academy of Neurology
31st Annual Meeting in Monterrey, Mexico (Oct. 31 - Nov. 5, 2007)
European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)
23rd Congress in Prague, Czech Republic (Oct. 11-14, 2007)
Colombian Academy of Neurology
VIII Meeting in Cali, Colombia (Aug. 16-19, 2007)
Consortium of Multiple Sclerosis Centers (CMSC)
21st Annual Meeting in Washington, DC (May 30 - June 2, 2007)
American Academy of Neurology (AAN)
59th Annual Meeting in Boston, Mass. (April 28 - May 5, 2007)
Mexican Academy of Neurology
30th Annual Meeting in Merida, Yucatan, Mexico (Oct. 30 - Nov. 4, 2006)
American Academy of Neurology (AAN)
58th Annual Meeting in San Diego, Calif. (April 1-8, 2006)
Mexican Academy of Neurology
29th Annual Meeting in Chihuahua, Mexico (Oct. 29 - Nov. 3, 2005)